explore -WSS

explore

author：knowledge 2025-09-29 13:09:29 - browse：366

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Stanford updates investigation of president’s past research

focus

WSS

New warning issued for rebooking air travel after delays, cancellations

Scientists inch closer to single

Seattle police shoot person suspected in downtown stabbing

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

India sets sights on home

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

focus

explore

entertainment

United colonoscopy coverage change 'may cost lives,' doctors say

India sets sights on home

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Adults seen as increasingly susceptible to measles

Hepatitis C has a cure — but many Americans still lack access to it

What the US credit downgrade means for the economy, your finances

Moonlake's readout produced a cash windfall. Risks remain

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

ChatGPT in medicine: STAT answers readers' burning questions

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

focus

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Sage hopes for a blockbuster in antidepressant now before FDA

Adults seen as increasingly susceptible to measles

TikTok cracks down on users posting about weight loss drugs

Micronoma's microbiome cancer diagnostic approach under fire

States increasingly look to regulate hospital facility fees

focus

explore

explore

explore